Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.
Age
10–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Part 1:
Participants with genetically confirmed diagnosis of XLRP (with RPGR mutation).
Participant with active disease clinically visible within the macular region in both eyes.
Part 2:
\- Participant with mean total retinal sensitivity in the study eye as assessed by microperimetry ≥ 0.1 dB and ≤8 dB.
You may not be if
Parts 1 and 2:
Participant with history of amblyopia in either eye.
Participated in a gene therapy trial previously or a clinical trial with an investigational drug in the past 12 weeks or received a gene/cell-based therapy at any time previously.
Clareo Health | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
